OncoMatch/Clinical Trials/NCT00107289
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Is NCT00107289 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies iobenguane I 131 for neuroblastoma.
Treatment: iobenguane I 131 — The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroblastoma
Disease stage
Required: Stage PROGRESSIVE, REFRACTORY
history of tumor progression or recurrence or failure to achieve complete response with standard therapy; evaluable disease on MIBG scan
Lab requirements
Kidney function
grade 2 or less renal toxicity
Liver function
grade 2 or less hepatic toxicity
Cardiac function
grade 2 or less cardiac toxicity
renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less. A grade 3 hearing deficit is acceptable.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify